Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1489-1495

  Wright, Elizabeth A ^a   Katz, Jeffrey N ^a   Abrams, Stanley ^a   Solomon, Daniel H ^a   Losina, Elena ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; HYDROCODONE; IBUPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; OPIATE; OXYCODONE; ROFECOXIB; TRAMADOL; NARCOTIC ANALGESIC AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HEALTH SURVEY; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MUSCULOSKELETAL DISEASE; OBESITY; PRESCRIPTION; SELF REPORT; CLINICAL PRACTICE; DRUG USE; HEALTH CARE SURVEY; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS, KNEE; PREVALENCE; RISK; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HEALTH CARE SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; OSTEOARTHRITIS, KNEE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84908521045     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22360     Document Type: Article

References (46)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008;58:26-35.
2. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010;26:355-69.
3. Niu J, Zhang YQ, Torner J, Nevitt M, Lewis CE, Aliabadi P, et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis? Arthritis Rheum 2009;61:329-35.
4. Adebajo A. Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care. BMC Fam Pract 2012; 13:23.
5. Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011.
6. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000.
7. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): American Academy of Orthopaedic Surgeons; 2008.
8. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-46.
9. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59: 936-44.
10. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10: 113-30.
11. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-74.
12. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
13. Couzin J. Drug safety: withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004;306:384-5.
14. U.S. Food and Drug Administration. COX-2 selective and non-selective non-steroidal anti-inflammatory drugs. URL: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafety informationforpatientsandproviders/ucm103420.htm.
15. Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010;170:1979-86.
16. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;3:CD004959.
17. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94.
18. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-5.
19. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12:657-67.
20. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain 2011;27:194-202.
21. Red Book. Pharmacy's fundamental reference: 2012 edition. Montvale (NJ): Thomson Healthcare; 2012.
22. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-76.
23. Anastassopoulos KP, Chow W, Tapia CI, Baik R, Ackerman SJ, Biondi D, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manag Care Pharm 2012;18:615-26.
24. Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction 2010;105: 2062-70.
25. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville (MD): US Department of Health and Human Services; 2011.
26. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med 2012;6:e41-7.
27. Campbell CI, Weisner C, Leresche L, Ray GT, Saunders K, Sullivan MD, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010; 100:2541-7.
28. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011; 5:e13-22.
29. Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009; 18:1166-75.
30. Solomon DH, Avorn J, Wang PS, Vaillant G, Cabral D, Mogun H, et al. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum 2006;55: 35-41.
31. Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington state workers' compensation, 1996-2002. Am J Ind Med 2005; 48:91-9.
32. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Australia 2011;195:280-4.
33. Ponizovsky AM, Marom E, Zeldin A, Cherny NI. Trends in opioid analgesics consumption, Israel, 2000-2008. Eur J Clin Pharmacol 2011;67:165-8.
34. Fisher JE, Ballantyne PJ, Hawker GA. Older adults living with osteoarthritis: examining the relationship of age and gender to medicine use. Can J Aging 2012;31:323-33.
35. Braden JB, Sullivan MD, Ray GT, Saunders K, Merrill J, Silverberg MJ, et al. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry 2009;31:564-70.
36. Pham K, Hirschberg R. Global safety of coxibs and NSAIDs. Curr Top Med Chem 2005;5:465-73.
37. Wolfe S, Suzman D, Jonasson U, Jonasson B. Petition to ban all propoxyphene (Darvon) products. 2006. URL: http://www. citizen.org/Page.aspx?pid=697.
38. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16: 137-62.
39. Rolita L, Spegman A, Tang X, Cronstein BN. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Ger Soc 2013;61:335-40.
40. Cicero TJ, Inciardi JA, Adams EH, Geller A, Senay EC, Woody GE, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005;14:851-9.
41. Reid MC, Shengelia R, Parker SJ. Pharmacologic management of osteoarthritis-related pain in older adults. Am J Nurs 2012; 112 Suppl 1:S38-43.
42. Large RG, Schug SA. Opioids for chronic pain of nonmalignant origin: caring or crippling. Health Care Anal 1995; 3:5-11.
43. Zywiel MG, Stroh DA, Lee SY, Bonutti PM, Mont MA. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg Am 2011;93:1988-93.
44. Parker Vail T. Preoperative pain management decisions impact outcome after total knee arthroplasty: implications for opiate use. Commentary on an article by Michael G. Zywiel, MD, et al.: "Chronic opioid use prior to total knee arthroplasty" [letter]. J Bone Joint Surg 2011;93:e1291-1.
45. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013;310:1263-73.
46. Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004;50:1501-10.